Beijing Chunlizhengda Medical Instruments Co., Ltd. (Chunli Medical) announced that all proposals put to vote at its 25 June 2026 Extraordinary General Meeting (EGM) were approved, clearing the way for a refreshed board structure and updated remuneration policies.
Key Meeting Data • 43 shareholders and proxies attended, representing 230.84 million voting shares—60.40% of the 382.19 million shares eligible to vote. • A-share holders accounted for 55.45% of total voting shares, while H-share holders represented 4.95%. • Wuyige Certified Public Accountants LLP acted as vote scrutineer, and V&T Law Firm confirmed the meeting’s legal compliance.
Approved Resolutions 1. Remuneration System for Directors and Senior Management • For: 99.67% (230.09 million votes) • Against/Abstain: 0.33%
2. Independent Non-Executive Directors’ (INEDs) Remuneration Package • For: 99.67% (230.09 million votes) • Against/Abstain: 0.33%
3. Election of Non-Independent Directors (cumulative voting) • Executive Directors: Shi Wenling (98.61% support), Shi Chunbao (99.42%), Yue Shujun (99.42%) • Non-Executive Director: Wang Xin (99.42%)
4. Election of Independent Non-Executive Directors (cumulative voting) • Xu Hong (99.53%), Zheng Zhongliang (99.69%), Kwan King Nam (99.69%)
Board Changes • Retiring INEDs: Wong Tak Shing and Weng Jie stepped down at the close of the EGM. • Newly elected sixth-session board now comprises: – Executive Directors: Shi Wenling (Chairman), Shi Chunbao, Yue Shujun, Xie Feng Bao (employee representative) – Non-Executive Director: Wang Xin – Independent Non-Executive Directors: Xu Hong, Zheng Zhongliang, Kwan King Nam • Directors’ terms commenced 25 June 2026 and will run through the end of the sixth board session; service contracts will be executed accordingly.
Regulatory Compliance The meeting’s convening procedures, attendee eligibility, and voting outcomes were deemed legal and valid under PRC law, the Hong Kong Listing Rules, and the company’s Articles of Association.
The resolutions’ passage secures Chunli Medical’s governance framework for the next board cycle and implements an updated remuneration structure aligned with shareholder approval.